Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Black Diamond Therapeutics, Inc. (BDTX) had Return on Tangible Equity of -6.74% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-8.50M |
|
-- |
|
-- |
|
$10.98M |
|
$-10.98M |
|
$2.48M |
|
$-8.50M |
|
$-8.50M |
|
$-8.50M |
|
$-8.50M |
|
$-8.50M |
|
$-8.50M |
|
$-10.98M |
|
$-10.89M |
|
56.93M |
|
56.93M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$138.99M |
|
$1.13M |
|
$18.74M |
|
$157.73M |
|
$15.54M |
|
-- |
|
$16.04M |
|
$31.58M |
|
$126.15M |
|
$126.15M |
|
$126.15M |
|
56.94M |
|
| Cash Flow Statement Financials | |
$36.40M |
|
$-42.02M |
|
$0.05M |
|
$37.26M |
|
$31.69M |
|
$-5.57M |
|
$5.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.94 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$36.42M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.74% |
|
|
Return on Tangible Equity |
-6.74% |
-5.39% |
|
-6.74% |
|
$2.22 |
|
$0.64 |
|
$0.64 |
|